Scinai Immunotherapeutics (SCNI) Earnings Forecast
What Wall Street expects this business to earn, and how much analysts disagree.
Are estimates going up or down lately?
We hold no eps window in 90 days for the near year yet. Every figure here compares one fiscal period at both ends.
No step line for this window yet. A line needs two nights of one fiscal period inside the window to join, and our record does not hold two.
| EPS | 30 days | 90 daysshown above | Since Jul 10 |
|---|---|---|---|
| Dec '261 analyst | ◆ 0.0%$−8.50 to $−8.50 | 86 of 90 days0.0% so far | ◆ 0.0%$−8.50 to $−8.50 |
| Mar '271 analyst | 5 of 30 days0.0% so far | 5 of 90 days0.0% so far | ◆ 0.0%$−85.00 to $−85.00 |
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
What you pay for the growth
We hold no forward multiple for Scinai Immunotherapeutics today, so there is nothing here to set against the growth the Street expects.
Is next quarter a high bar or an easy one?
Analysts expect Scinai Immunotherapeutics to lose $8.50 a share in the December quarter, the one estimate published. We hold no expected date for the next report.
For the March quarter, analysts expect a loss of $85.00 a share.
Does Scinai Immunotherapeutics usually beat or miss?
We have not been able to check a quarter yet. Our record of estimates for Scinai Immunotherapeutics begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.
We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Scinai Immunotherapeutics on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: no near-year analyst count published. Not investment advice.

